Jean-Noel Freund
  • E-mail :[email]
  • Phone : +33 3 88 27 77 27 (std)
  • Location : INSERM UMR-S1113; Strasbourg, France
Last update 2018-04-21 11:00:11.219

Jean-Noel Freund PhD, Molecular and Cellular Biology

Course and current status

Director of the UMR-S1113 / IRFAC of INSERM & University of Strasbourg:

Interface between Basic and Applied Cancer Research

Leader of Team 1Stem Cell Emergence & Tumor Initiation

                                            - - - - - - - - - - - -

PhD in Cellular and Molecular Biology, University Louis Pasteur, Strasbourg, France (1986): "The rudimentary gene of Drosophila melanogaster: structure, expression and function" (LGME Inserm U184, supervisor: Prof P Chambon).   

Scientific summary

The translational cancer research laboratory of INSERM and University of Strasbourg, UMR-S1113 / IRFAC, is located nearby the University Hospital of Strasbourg-Hautepierre, in close vicinity of the clinical Regional Institute of Cancer. It consists of basic scientists, clinicians and methodologists whose goal is to provide a better understanding of (i) the mechanisms of tumor initiation (Team 1) and (ii) the response to treatments (Team 2), with the aim of developing innovative therapies.

It is composed of 2 teams.

> Team 1 (Leader JN Freund): Stem Cell Emergence & Tumor Initiation.

> Team 2 (Leader C Gaiddon): Stress Response & Innovative Therapy.

                                                       --------------------

Team 1.

The Team "Stem Cell Emergence & Tumor Initiation" investigates the mechanisms of embryogenesis and tissue homeostasis, whose alteration is involved in tumor initiation.  It comprises 2 groups entitled «Intestinal Identity: from Stem Cells to Pathologies» and «Human Hematopoiesis and Leucemogenesis» focusing on the digestive and hematopoietic systems. Studies concern stem cells, cancer stem cells and their interactions with the niches and the cellular and molecular microenvironment. Particular attention is paid (i) to cell interactions involving cytokines (CXCL12) and hormones (Angiotensin), (ii) to the evolution of cellular programs and (iii) to homeotic transcription factors (Cdx2) and their targets and partners (Mucdhl, KU70/80, ASF/SF2, SRp30c), that are altered during the process of tumor initiation.

Image d’exemple